A letter from the House and Senate argues federal mail-order rules violate states’ rights and threaten women’s health.
Abortion medication access, like mifepristone, is unchanged under Trump, but FDA reviews, lawsuits and state enforcement are creating risks for drugmakers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback